Phaseline

Companies › Neurocrine Biosciences

Neurocrine Biosciences: clinical trials, targets and expected readouts

6 active drug programs in 17 registered trials: 11 Phase 3, 5 Phase 2, 1 Phase 4; Psychiatry, Neurology, Genitourinary; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Valbenazine
Synaptic vesicular amine transporter inhibitor
SLC18A2Phase 4Schizophrenia; Trichotillomania (Hair-Pulling Disorder); Cervical DystoniaJun 2028
Osavampator (NBI-1065845)
Glutamate receptor ionotropic AMPA positive allosteric modulator
GRIA4, GRIA3, GRIA2, GRIA1Phase 3Major Depressive DisorderJul 2027
Crinecerfont
Corticotropin releasing factor receptor 1 antagonist
CRHR1Phase 3Congenital Adrenal HyperplasiaAug 2027
NBI-1117568–Phase 3Schizophrenia; Bipolar I DisorderOct 2027
NBI-1065890
Vesicular monoamine transporter 2 (VMAT2) inhibitor
VMAT2Phase 2Tardive DyskinesiaFeb 2027
NBI-1117570–Phase 2SchizophreniaAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07365462NBI-1065890Phase 2Tardive DyskinesiaNeurologyFeb 2027
NCT05207085ValbenazinePhase 2Trichotillomania (Hair-Pulling Disorder)PsychiatryFeb 2027
NCT06771323ValbenazinePhase 2Cervical DystoniaNeurologyJun 2027
NCT06786624Osavampator (NBI-1065845)Phase 3Major Depressive DisorderPsychiatryJul 2027
NCT06911112Osavampator (NBI-1065845)Phase 3Major Depressive DisorderPsychiatryJul 2027
NCT06963021Osavampator (NBI-1065845)Phase 3Major Depressive DisorderPsychiatryJul 2027
NCT04490915CrinecerfontPhase 3Congenital Adrenal HyperplasiaGenitourinaryAug 2027
NCT04806451CrinecerfontPhase 3Congenital Adrenal HyperplasiaGenitourinaryAug 2027
NCT07288333NBI-1117570Phase 2SchizophreniaPsychiatryAug 2027
NCT06963034NBI-1117568Phase 3SchizophreniaPsychiatryOct 2027
NCT07105098NBI-1117568Phase 3SchizophreniaPsychiatryNov 2027
NCT07288320NBI-1117568Phase 2Bipolar I DisorderPsychiatryFeb 2028
NCT07105111ValbenazinePhase 4SchizophreniaPsychiatryJun 2028
NCT07196501Osavampator (NBI-1065845)Phase 3Major Depressive DisorderPsychiatryJul 2028
NCT06966401Osavampator (NBI-1065845)Phase 3Major Depressive DisorderPsychiatryMay 2029
NCT07227818NBI-1117568Phase 3SchizophreniaPsychiatryJul 2029
NCT07114874NBI-1117568Phase 3SchizophreniaPsychiatryDec 2031

From the company's SEC filings

Cash and short-term investments of $738m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

VMAT2 (1) SLC18A2 (1) GRIA4 (1) GRIA3 (1) GRIA2 (1) GRIA1 (1) CRHR1 (1)

Companies with the same targets

Eisai Proniras Upsher-Smith Laboratories

Companies built like this

Alkermes Supernus Pharmaceuticals Definium Therapeutics US Intra-Cellular Therapies ACADIA Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.